EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about ...
RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib ...
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Oropharyngeal Cancer. According to GlobalData, Phase III drugs for Oropharyngeal Cancer have a 17% phase ...
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Hypopharyngeal Cancer.
The company's focus is now on its drug zanzalintinib, which is currently undergoing trials for colorectal cancer. However, BMO Capital Markets and BofA Securities have both downgraded Exelixis due to ...
The company's focus is now on its drug zanzalintinib, which is currently undergoing trials for colorectal cancer. However, BMO Capital Markets and BofA Securities have both downgraded Exelixis due ...
The focus now turns to Exelixis's drug zanzalintinib, a multi-kinase inhibitor currently undergoing trials for colorectal cancer (CRC). While the probability of success for zanzalintinib in CRC ...
The firm has raised its target on zanzalintinib’s probability of success in CRC, which it now pegs at 50%, but views the success of the trial as “a toss-up” given the history of cabometyx ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback